Results 31 to 40 of about 7,743 (211)

Cannabinoids and Dementia: A Review of Clinical and Preclinical Data [PDF]

, 2010
The endocannabinoid system has been shown to be associated with neurodegenerative diseases and dementia. We review the preclinical and clinical data on cannabinoids and four neurodegenerative diseases: Alzheimer’s disease (AD), Huntington’s disease (HD),
Aarsland, Aiken, Allen, Aso, Bal-Price, Bambico, Basavarajappa, Bellocchio, Benito, Benito, Blennow, Breivogel, Campbell, Campillo, Cao, Carroll, Centonze, Cernak, Citron, Consroe, Consroe, Cummings, Curtis, Curtis, Curtis, de Lago, De March, Denovan-Wright, Di Marzo, Di Marzo, Ehrhart, Esposito, Esposito, Esposito, Esposito, Eubanks, Fernandez-Espejo, Fernandez-Ruiz, Ferri, Fox, Gaoni, Garcia-Arencibia, Gerdeman, Gilgun-Sherki, Glass, Glass, Glass, Glass, Grunblatt, Gubellini, Hansen, Hayakawa, Herkenham, Hillard, Howlett, Howlett, Iuvone, Iuvone, Jimenez-Del-Rio, Katona, Katona, Katona, Kelsey, Khaspekov, Kirshner, Krishnan, Kumar, Lastres-Becker, Lastres-Becker, Lastres-Becker, Lastres-Becker, Lastres-Becker, Lastres-Becker, Lastres-Becker, Lees, Leker, Leys, Louw, Maneuf, Mangieri, Marchalant, Marchalant, Maresz, Marsicano, Matsuda, Mauler, McCaw, Meschler, Mesnage, Michael Halpern, Milton, Molina-Holgado, Morgese, Muller-Vahl, Munro, Murillo-Rodriguez, Murillo-Rodriguez, Nagayama, Pacher, Palazuelos, Parmentier-Batteur, Passmore, Pavese, Pellegrini-Giampietro, Pertwee, Price, Ramirez, Richfield, Sapp, Savva, Sebastian Walther, Shen, Shen, Sieradzan, Silverdale, Staekenborg, Tai, Tolon, van der Stelt, van der Stelt, van Vliet, Venderova, Volicer, Walker, Walsh, Walter, Walther, Wegener, Westlake, Wilson, Zani, Zhu, Zuardi   +132 more
core   +2 more sources

Cannabis therapy in neurological disorders: Recent advances and perspectives [PDF]

Romanian Journal of Pharmaceutical Practice, 2020
Both phytocannabinoids (Δ9-tetrahydrocannabinol, cannabidiol) and synthetic derivatives (nabilone, dronabinol) showed therapeutic benefits in some neurological disorders.
Alexandru Mandici, Daniel Cojocariu, Anca Miron   +2 more
doaj   +1 more source

End-of-life care and dementia [PDF]

, 2006
In the UK, research continues to confirm that people with certain chronic illnesses, such as chronic lung disease and cardiac failure, represent the ‘disadvantaged dying’ compared to those with terminal cancer.
Ballard, Clive, Daley, Sarah, Hughes, Julian, Keady, John, Robinson, Louise, Volicer, Ladislav   +5 more
core   +1 more source

Grinding and Fractionation during Distillation Alter Hemp Essential Oil Profile and Its Antimicrobial Activity

Molecules, 2020
The hypothesis of this study was that we can modify the essential oil (EO) profile of hemp (Cannabis sativa L.) and obtain fractions with differential composition and antimicrobial activity.
Valtcho D. Zheljazkov, Vladimir Sikora, Ivanka B. Semerdjieva, Miroslava Kačániová, Tess Astatkie, Ivayla Dincheva   +5 more
doaj   +1 more source

Case Report: Secondary bilateral parkinsonism and dystonia treated with dronabinol [version 3; peer review: 2 approved]

F1000Research, 2021
Drug abuse may damage basal ganglia that are essential for planning and execution of movements. We report about the case of a 38-year old patient with ischemic lesions of the basal ganglia presenting with bilateral painful dystonia and parkinsonism ...
Natalia Szejko, Florian Burger, Victoria Sidoroff, Gregor K. Wenning   +3 more
doaj   +1 more source

Industrial, CBD, and Wild Hemp: How Different Are Their Essential Oil Profile and Antimicrobial Activity?

Molecules, 2020
Hemp (Cannabis sativa L.) is currently one of the most controversial and promising crops. This study compared nine wild hemp (C. sativa spp. spontanea V.) accessions with 13 registered cultivars, eight breeding lines, and one cannabidiol (CBD) hemp ...
Valtcho D. Zheljazkov, Vladimir Sikora, Ivayla Dincheva, Miroslava Kačániová, Tess Astatkie, Ivanka B. Semerdjieva, Dragana Latkovic   +6 more
doaj   +1 more source

Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials

Frontiers in Psychiatry, 2022
BackgroundThe prevalence of cannabis use and cannabis use disorders (CUD) has significantly increased over time. However, there are no approved pharmacological treatments for CUD.
Caroline Vuilleumier, Norbert Scherbaum, Udo Bonnet, Udo Bonnet, Patrik Roser, Patrik Roser   +5 more
doaj   +1 more source

Therapeutical use of the cannabinoids in psychiatry [PDF]

, 2010
OBJETIVO: Revisar os principais avanços no potencial uso terapêutico de alguns compostos canabinoides em psiquiatria. MÉTODO: Foi realizada busca nos bancos de dado PubMed, SciELO e Lilacs e identificados estudos e revisões da literatura sobre o uso ...
CRIPPA, José Alexandre S., HALLAK, Jaime E. C., ZUARDI, Antonio Waldo   +2 more
core   +2 more sources

Treating nightmares in posttraumatic stress disorder with dronabinol: study protocol of a multicenter randomized controlled study (THC PTSD-trial)

BMC Psychiatry, 2023
Background Distressing nightmares are a core symptom of posttraumatic stress disorder (PTSD) and contribute to psychiatric comorbidity, impaired physical health and decreased social functioning.
Stefan Roepke, Nikola Schoofs, Kathlen Priebe, Felix Wülfing, Christian Schmahl, Robert Röhle, Jenny Zähringer, Tobias Lotter, Christian Otte, Stefanie Koglin   +9 more
doaj   +1 more source

Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples

Metabolites, 2021
Increasing prescription numbers of cannabis-based medicines raise the question of whether uptake of these medicines can be distinguished from recreational cannabis use. In this pilot study, serum cannabinoid profiles after use of cannabis-based medicines
Anne Scheunemann, Katrin Elsner, Tanja Germerott, Sergiu Groppa, Cornelius Hess, Isabelle Miederer, Alicia Poplawski, Jörg Röhrich   +7 more
doaj   +1 more source